A 45-year-old man with severe ARDS from an emerging viral infection has been on veno-venous ECMO, mechanical ventilation via tracheostomy, and continuous vasopressor support for refractory shock for 3 weeks. Attempts at ventilator weaning have repeatedly failed. He is unable to communicate, and no advance directive or code-status discussion has occurred. His family is increasingly distressed about his prolonged critical state and the risk of severe long-term impairment. Which of the following is the highest priority intervention at this stage of care?

A 45-year-old man, admitted to the critical care unit 7 days ago for severe SARS-CoV-2 pneumonia, remains on assist-control ventilation with a PEEP of 12 cm H₂O and an FiO₂ of 0.6. He is receiving a continuous propofol infusion at 20 mcg/kg/min for sedation and has a central venous catheter in place. Despite initial therapy, his respiratory status remains critical, and he has developed significant muscle weakness. Given the patient’s prolonged mechanical ventilation and deep sedation, which of the following interventions is MOST effective for mitigating the risk of Post-ICU Syndrome (PICS)?

A 62-year-old man with type 2 diabetes (HbA1c 7.2%) and obesity (BMI 35 kg/m2) is in the ICU for severe COVID-19 pneumonia, on mechanical ventilation and a norepinephrine infusion. He’s receiving dexamethasone 6 mg IV daily. On day 3, his glucose readings are 250–350 mg/dL despite basal insulin glargine 30 units nightly and a sliding-scale insulin aspart regimen. His current glucose is 310 mg/dL, and nursing reports frequent correction doses. Which of the following is the MOST appropriate immediate pharmacologic intervention to optimize glycemic control?

A 68-year-old man with end-stage renal disease on thrice-weekly hemodialysis, poorly controlled type 2 diabetes mellitus, and coronary artery disease is admitted to the ICU with severe COVID-19 pneumonia. He is intubated for respiratory failure and requires norepinephrine for hypotension. His SARS-CoV-2 PCR is positive. Laboratory studies show creatinine 6.8 mg/dL and estimated GFR <15 mL/min/1.73 m². Which of the following antiviral agents is the most appropriate initial therapy for his SARS-CoV-2 infection?

A 62-year-old man is admitted to the ICU for severe COVID-19 pneumonia and septic shock. He is on assist-control ventilation with a midazolam infusion (5 mcg/kg/min), fentanyl infusion (50 mcg/hr), dexmedetomidine infusion (0.7 mcg/kg/hr), norepinephrine at 0.1 mcg/kg/min via a right internal jugular central line, vancomycin, and meropenem. His history includes diabetes and obesity. Five days ago he completed a 5-day outpatient course of nirmatrelvir/ritonavir 300 mg/100 mg orally twice daily. Current labs: serum creatinine 2.8 mg/dL (baseline 1.0 mg/dL), eGFR 25 mL/min/1.73 m2, AST 65 U/L, ALT 70 U/L. Given his recent ritonavir exposure and current medications, which of the following is the most important immediate consideration?

A 68-year-old man presents on hospital day 2 with new-onset cough, fever (38.2 °C), and increased dyspnea 4 days after symptom onset of confirmed SARS-CoV-2 infection. He completed a two-dose mRNA COVID-19 vaccine series 6 months ago without a booster. His history includes type 2 diabetes, heart failure (NYHA II), and chronic kidney disease stage 3a (eGFR 45 mL/min/1.73 m²). He is currently on 3 L/min nasal cannula to maintain SpO₂ 92% (baseline 94% on room air). He is hemodynamically stable with no increased work of breathing. Which of the following is the MOST appropriate initial antiviral therapy?

A 62-year-old man with type 2 diabetes mellitus and obesity was admitted to the ICU 8 days ago for severe COVID-19. He required high-flow nasal cannula and had a central venous catheter placed for fluid resuscitation; both have since been discontinued. He completed a 3-day course of intravenous remdesivir. He reports that his symptoms began 12 days ago; he is now afebrile, hemodynamically stable, and maintaining an oxygen saturation of 96% on room air. Which of the following is the most appropriate pharmacologic plan for this patient’s COVID-19 upon discharge?

A 65-year-old man is admitted to the critical care unit with severe COVID-19 pneumonia. He is managed with assist-control ventilation and a norepinephrine infusion via a central line to maintain mean arterial pressure. He was initiated on nirmatrelvir/ritonavir 300 mg/100 mg orally every 12 hours upon admission, when his eGFR was 75 mL/min. On hospital day 3, his eGFR drops to 45 mL/min. He is also receiving a continuous infusion of midazolam for sedation. Given the change in renal function, which of the following is the most appropriate adjustment to the antiviral regimen?

A 62-year-old unvaccinated man is admitted to the intensive care unit for close observation after 4 days of worsening dyspnea and hypoxemia due to confirmed COVID-19. On room air, his SpO₂ is 90%; with 4 L/min oxygen via nasal cannula, his SpO₂ rises to 95%. His medical history includes type 2 diabetes mellitus, hypertension, and chronic kidney disease (baseline eGFR 45 mL/min/1.73 m²), with acute worsening to an eGFR of 25 mL/min/1.73 m² on admission. Baseline liver function tests (ALT, AST) are within normal limits. Symptoms began 4 days ago. Which of the following is the most appropriate initial antiviral therapy?

A 62-year-old patient is admitted to the intensive care unit for severe acute respiratory distress syndrome (ARDS) secondary to a confirmed emerging viral infection. The patient is on assist-control mechanical ventilation with an FiO2 of 0.8 and PEEP of 12 cmH2O and is receiving a continuous norepinephrine infusion via a central line. Which statement best characterizes the evidence-based pharmacologic management for this patient’s level of disease severity?